The Serum Institute of India announced in the middle of a major uproar over the side effects of Covishield that it will no longer be producing or supplying more doses of the vaccine starting in December 2021. This decision was made in light of the sharp decline in demand for earlier versions of the vaccine.
“The need for earlier vaccinations drastically decreased as a result of new mutant variant strains emerging and India reaching high immunization rates in 2021 and 2022.As a result, we have ceased producing and supplying extra doses of Covishield as of December 2021,” a SII representative stated on Wednesday.
“Have disclosed all side effects in packaging”
The Serum Institute of India has responded to the adverse effects of the vaccine by stating that, since 2021, all uncommon to extremely rare side effects have been disclosed in the vaccine’s package. “We must underline our dedication to safety and openness since we are aware of the persistent concerns. The SII representative stated, “From the beginning, we have disclosed all rare to very rare side effects in the packaging insert in 2021, including thrombosis with thrombocytopenia syndrome.”
Thrombosis with thrombocytopenia syndrome, or TTS, is an uncommon adverse effect of the vaccination that AstraZeneca acknowledged in court documents, raising concerns about the vaccine’s possible health implications. A rare but dangerous illness known as thrombosis with thrombocytopenia syndrome (TTS) is characterized by low platelet counts and the production of blood clots.
Usually associated with specific COVID-19 vaccinations, TTS presents as hematomas in atypical locations including the belly or brain, along with a decrease in platelets. Severe headaches, stomach pain, and neurological impairments are among the symptoms. Timely medical intervention is essential since TTS can result in potentially fatal consequences such as stroke or organ damage. Hospitalization, blood thinners, and strict observation are common treatment modalities.